Report cover image

Irritable Bowel Syndrome Treatment Market - 2025-2033

Publisher DataM Intelligence 4Market Research LLP
Published Apr 07, 2026
Length 219 Pages
SKU # DTAM21129890

Description

Irritable Bowel Syndrome Treatment Market Overview:
The Irritable Bowel Syndrome Treatment Market was valued at US$ 3.93 billion in 2025 and is anticipated to reach US$ 7.68 billion by 2033, at a CAGR of 0.088 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Irritable Bowel Syndrome Treatment Market.

This report delivers a comprehensive overview of the Irritable Bowel Syndrome Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Irritable Bowel Syndrome Treatment Market. The Irritable Bowel Syndrome Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Irritable Bowel Syndrome Treatment Market Scope:
Key Players
• Procter & Gamble
• Haleon Group of Companies.
• Teva Pharmaceutical Industries Ltd.
• Ironwood Pharmaceuticals, Inc.
• AbbVie.
• Salix Pharmaceuticals
• Foundation Consumer Brands.
• Kenvue Brands LLC.
• Pfizer Inc.
• Upsher-Smith Laboratories, LLC.
• Sanofi
• Bayer AG
• Atlantis Consumer Healthcare Inc.
• Alfasigma Group
• Takeda Pharmaceutical Company Limited.
• Ardelyx.

Major Highlights
This report delivers a comprehensive overview of the Irritable Bowel Syndrome Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Irritable Bowel Syndrome Treatment Market. The Irritable Bowel Syndrome Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

219 Pages
1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
3. Market Highlights and Strategic Takeaways
3.1. Key Trends and Future Projections
4. Snippet by Disease Type
5. Snippet by Drug Class
5.1. Snippet by Region
6. Dynamics
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Prevalence of Irritable Bowel Syndrome
7. Rising Novel Product Approvals
8. Restraints
8.1. Availability of Limited Treatment Options
8.1.1. Underdiagnosis of IBS
9. Opportunities
9.1. Increasing Patient Awareness and Advocacy Programs
9.1.1. Development of Microbiome-Based Therapies
9.1.2. Impact Analysis
10. Strategic Insights and Industry Outlook
10.1. Market Leaders and Pioneers
10.1.1. Emerging Pioneers and Prominent Players
10.1.2. Established Leaders with the Largest Marketing Brand
10.1.3. Market Leaders with Established Products
10.2. Latest Developments and Breakthroughs
10.3. Regulatory and Reimbursement Landscape
10.3.1. North America
10.3.2. Europe
10.3.3. Asia Pacific
10.3.4. Latin America
10.3.5. Middle East & Africa
10.4. Porter’s Five Forces Analysis
10.5. Supply Chain Analysis
10.6. Patent Analysis
10.7. SWOT Analysis
10.8. Pipeline Analysis
10.9. Epidemiology Analysis
10.10. Unmet Needs and Gaps
10.11. Recommended Strategies for Market Entry and Expansion
10.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
10.13. Pricing Analysis and Price Dynamics
11. Global Irritable Bowel Syndrome Treatment Market, By Disease Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.1.2. Market Attractiveness Index, By Disease Type
11.2. IBS with Diarrhea (IBS-D) *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. IBS with Constipation (IBS-C)
11.4. Mixed-Presentation IBS (IBS-M)
11.5. Undefined IBS (IBS-U)
12. Global Irritable Bowel Syndrome Treatment Market, By Drug Class
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.1.2. Market Attractiveness Index, By Drug Class
12.2. Antispasmodics
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Antidiarrheal Medication
12.4. Laxatives
12.5. Antibiotics
12.6. Antidepressants
12.7. Fiber Supplements
12.8. Secretagogues
12.9. Others
13. Global Irritable Bowel Syndrome Treatment Market, By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.5.1. U.S.
13.2.5.2. Canada
13.2.5.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.5.1. Germany
13.3.5.2. U.K.
13.3.5.3. France
13.3.5.4. Spain
13.3.5.5. Italy
13.3.5.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.5.1. Brazil
13.4.5.2. Argentina
13.4.5.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.5.1. China
13.5.5.2. India
13.5.5.3. Japan
13.5.5.4. South Korea
13.5.5.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
14. Competitive Landscape and Market Positioning
14.1. Competitive Overview and Key Market Players
14.2. Market Share Analysis and Positioning Matrix
14.3. Strategic Partnerships, Mergers & Acquisitions
14.4. Key Developments in Product Portfolios and Innovations
14.5. Company Benchmarking
15. Company Profiles
15.1. Procter & Gamble*
15.1.1. Company Overview
15.1.2. Product Portfolio
15.1.2.1. Product Description
15.1.2.2. Product Key Performance Indicators (KPIs)
15.1.2.3. Historic and Forecasted Product Sales
15.1.2.4. Product Sales Volume
15.1.3. Financial Overview
15.1.3.1. Company Revenue’s
15.1.3.2. Geographical Revenue Shares
15.1.3.3. Revenue Forecasts
15.1.4. Key Developments
15.1.4.1. Mergers & Acquisitions
15.1.4.2. Key Product Development Activities
15.1.4.3. Regulatory Approvals, etc.
15.1.5. SWOT Analysis
15.2. Haleon Group of Companies.
15.3. Teva Pharmaceutical Industries Ltd.
15.4. Ironwood Pharmaceuticals, Inc.
15.5. AbbVie.
15.6. Salix Pharmaceuticals
15.7. Foundation Consumer Brands.
15.8. Kenvue Brands LLC.
15.9. Pfizer Inc.
15.10. Upsher-Smith Laboratories, LLC.
15.11. Sanofi
15.12. Bayer AG
15.13. Atlantis Consumer Healthcare Inc.
15.14. Alfasigma Group
15.15. Takeda Pharmaceutical Company Limited.
15.16. Ardelyx. (*LIST NOT EXHAUSTIVE)
16. Appendix
16.1. About Us and Services
16.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us